Eli Lilly Pills - Search News

New weight loss pill to be approved by early 2026

Hosted on MSN · 1d

Eli Lilly CEO expects new weight loss pill to be approved next year

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.

YAHOO!Finance · 2d

Eli Lilly misses 2024 revenue numbers, but GLP-1 pill may help

Global pharmaceutical company Eli Lilly's (LLY) preliminary 2024 revenue missed expectations on lower-than-expected sales of its weight loss and diabetes shots. According to the company, sales are expected to hit $45 billion,

Becker's Hospital Review · 2d

New weight loss pill to be approved by early 2026: Eli Lilly

Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.

24/7 Wall St. on MSN1d

Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

GlobalData on MSN1d

JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400m

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Pfizer Cautiously Optimistic on Obesity Pill as Kailera Challenges Lilly’s Zepbound With Strong Phase II Data

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results